Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1556517 | 0.89 | ALDH1A1 (0.41) | LMNACYP2D6ALDH1A1 | |
| SCHEMBL16757153 | 0.77 | MEN1 (0.44) | KDM4EGAALMNACYP3A4CYP2D6 | |
| SCHEMBL9546413 | 0.77 | CYP3A4 (0.52) | KDM4EGAALMNACYP3A4CYP2D6 | |
| SCHEMBL24998568 | 0.73 | CYP2D6 (0.46) | CYP3A4CYP2D6ALDH1A1 | |
| SCHEMBL30067766 | 0.72 | CYP2D6 (0.44) | CYP3A4CYP2D6MEN1KMT2AALDH1A1 | |
| SCHEMBL23043010 | 0.71 | MEN1 (0.47) | KDM4EGAALMNACYP3A4CYP2D6 | |
| SCHEMBL18063152 | 0.71 | KDM4E (0.47) | KDM4EGAALMNACYP3A4CYP2D6 | |
| SCHEMBL7382094 | 0.71 | CYP2D6 (0.46) | CYP3A4CYP2D6MEN1KMT2AALDH1A1 | |
| SCHEMBL11301180 | 0.70 | CYP3A4 (0.53) | KDM4EGAALMNACYP3A4CYP2D6 | |
| SCHEMBL14673484 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105548-A1 | N-ARYL DIAZASPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TARGACEPT, INC. (US) | 2011-05-05 | — | — | US | disclosed |
| US-7923559-B2 | 7-(3-pyridyl)-1,7-diazaspiro[4.4]nonane; mania, anxiety, dyslexia, schizophrenia, depression, obsessive-compulsive disorders, Tourette's syndrome | TARGACEPT, INC. (US) | 2011-04-12 | — | — | US | disclosed |
| EP-1519939-B9 | N-ARYL DIAZASPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TARGACEPT INC (US) | 2011-04-06 | — | — | EP | disclosed |
| EP-1519939-B1 | N-ARYL DIAZASPIRACYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TARGACEPT INC (US) | 2009-12-09 | — | — | EP | disclosed |
| EP-2078718-A1 | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | Targacept, Inc. (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20080214591-A1 | N-Aryl Diazaspirocyclic Compounds and Methods of Preparation and Use Thereof | BHATTI BALWINDER S | 2008-09-04 | — | — | US | disclosed |
| US-7375110-B2 | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | TARGACEPT, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-7291731-B2 | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | TARGACEPT, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| EP-1784184-A2 | THE USE OF N-ARYL DIAZASPIRACYCLIC COMPOUNDS IN THE TREATMENT OF ADDICTION | Targacept, Inc. (US) | 2007-05-16 | — | — | EP | disclosed |
| US-20060217406-A1 | N-ARYL DIAZASPIRACYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | BHATTI BALWINDER S | 2006-09-28 | — | — | US | disclosed |
| US-20060058328-A1 | Use of N-aryl diazaspiracyclic compounds in the treatment of addiction | BHATTI BALWINDER S | 2006-03-16 | — | — | US | disclosed |
| WO-2006023630-A2 | THE USE OF N-ARYL DIAZASPIRACYCLIC COMPOUNDS IN THE TREATMENT OF ADDICTION | TARGACEPT, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20050272739-A1 | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | BHATTI BALWINDER S | 2005-12-08 | — | — | US | disclosed |
| US-6956042-B2 | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | TARGACEPT, INC. (US) | 2005-10-18 | — | — | US | disclosed |
| EP-1519939-A2 | N-ARYL DIAZASPIRACYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | Targacept, Inc. (US) | 2005-04-06 | — | — | EP | disclosed |
| US-20040067930-A1 | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | TARGACEPT, INC. | 2004-04-08 | — | — | US | disclosed |
| WO-2004005293-A2 | N-ARYL DIAZASPIRACYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TARGACEPT, INC. (US) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214591-A1 | N-Aryl Diazaspirocyclic Compounds and Methods of Preparation and Use Thereof | TNNC1, ACHE, CHRNA6 | KDM4E 3731/4885GAA 1231/4885LMNA 1674/4885 |
| US-20110105548-A1 | N-ARYL DIAZASPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TNNC1, ACHE, CHRNA6 | KDM4E 3731/4885GAA 1231/4885LMNA 1674/4885 |
| US-20060217406-A1 | N-ARYL DIAZASPIRACYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TNNC1, ACHE, CHRNA6 | KDM4E 3542/4885GAA 1112/4885LMNA 1687/4885 |
| US-20050272739-A1 | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | TNNC1, ACHE, CHRNA6 | KDM4E 3542/4885GAA 1112/4885LMNA 1687/4885 |
| US-20060058328-A1 | Use of N-aryl diazaspiracyclic compounds in the treatment of addiction | OPRD1, OPRK1, OPRL1 | KDM4E 1944/4885GAA 308/4885LMNA 4365/4885 |
| US-20040067930-A1 | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | TNNC1, ACHE, CHRNA6 | KDM4E 3542/4885GAA 1112/4885LMNA 1687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.